Clinical Trial Update: A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating 1200 mg vs 1800 mg rifampicin for pulmonary tuberculosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• Rifampicin

Snippet

Sponsor: St George's, University of London | Conditions: Pulmonary Tuberculosis | Phase 3 | Status: COMPLETED